

Has The Promise of non-  
invasive Glucose Testing Been  
Realized?  
Progress and Hurdles

Omar S. Khalil, Ph.D.

POCT meeting, Quebec City, Canada, 9/27-9-30,  
2006

# Progress?

- **Several published optical methods**
- **Determination of glucose in aqueous solutions by NIR, Raman, Mid-IR, close to the physiological concentration range**
- **Tracking of changes in glucose concentration during a meal tolerance test, glucose clamps, and spot tests**
- **Limited clinical studies**
- **The powerful mathematical algorithms used and limited data sets cast shadow on the validity of some methods**

# Hurdles/Limitations of non-invasive glucose testing

- Sensitivity
- Specificity
- Compartmentalization issues
- Body interface and physiological noise
- Multivariate calculations and error estimates

# Sensitivity

- **Very low molar absorptivity of glucose**
- **No enzyme amplification as in the in-vitro methods**
- **No colored substrates with high molar absorptivity (NADH or dyes)**
- **Undefined properties of optical window (skin)**

# Specificity

- **In vitro glucose determinations derive their specificity from the enzyme-substrate reaction**
- **NI glucose determinations derive their specificity from the use of multivariate calculations**
- **Require a training/calibration set to generate data from prediction data sets**
- **Overlap of calibration and prediction data sets And data over-fitting present major problems**

# Compartmentalization

- **In vitro Glucose determinations use venous or capillary blood outside the body in defined reaction vessels**
- **NI glucose methods sample tissue volumes that include cells, interstitial fluid, and arterial and venous blood**
- **Skin properties and body physiological response to glucose may affect signal**


# Calculations and error limits

- **In vitro glucose methods use single variable fit and calculate SD and CV that vary with glucose values**
- **NI methods use multivariate calculations that result in a constant standard error of prediction over the whole glucose range**
- **Even if all problems are solved NI will have a problem at low glucose (hypoglycemic) concentrations**

# Will discuss two issues

1. Role of the skin
2. Error limits
3. What is needed

# Localized reflectance of human skin




- Light is injected into the skin via a 400 micron fiber and collected at different distances

- Light intensity at each source-detector distance is determined


- Wavelengths 590 to 980 nm

- Temperature is controlled and varied via TE elements




Temperature controlled disc surrounding the optical fibers at center


# Temperature-modulated localized reflectance of human skin



Temp. Program 1



Temp. Program 2



Temp. Program 3

A function  $f$  is derived from optical signals at two areas of the skin:

$$f(\mathbf{R}_{A1T1}, \mathbf{R}_{A1T2}, \mathbf{R}_{A2T3}, \mathbf{R}_{A2T4}) = [\text{Ln}(\mathbf{R}_{A1T1} / \mathbf{R}_{A1T2})] - [\text{Ln}(\mathbf{R}_{A2T3} / \mathbf{R}_{A2T4})] \quad (1)$$

$\mathbf{R}_{A1Tj}$  is the localized reflectance within skin area  $i$  at time.  $f$  was determined at 4 source detector distances and at 4 wavelengths and used to generate a discriminant function

$$D = \sum_i \sum_j a_{ij} (\delta_i f_i) (\delta_j f_j) + \sum_i a_i \delta_i f_i + a_o \quad (2)$$

where

$$\delta_i = 1 \text{ or } 0; \quad \text{and} \quad \sum_i \delta_i = K \quad (3a)$$

$$\delta_j = 1 \text{ or } 0; \quad \text{and} \quad \sum_j \delta_j = K \quad (3b)$$

$a_{ij}$ ,  $a_i$ , and  $a_o$  are constants, and  $i$  or  $j$  are indices to specific combinations of wavelength and source-detector distance.  $K$  limited the total number of wavelength/source-detector distance combinations used in  $D$ , and  $\delta_i$  and  $\delta_j$  were determined from the training set through a leave-one-out cross validation procedure.

A subject is classified as diabetic if  $D > 0$ , and non-diabetic if  $D < 0$ .

**Prediction of the diabetic status at 120 seconds  
after probe-skin contact**

<b>Temp. program</b>	<b>Optical Test Result</b>	<b>True Status</b>	
		<b>Diabetic</b>	<b>Non-diabetic</b>
<b>1</b>	<b>Diabetic</b>	<b>11</b>	<b>3</b>
	<b>Non-diabetic</b>	<b>1</b>	<b>9</b>
<b>2</b>	<b>Diabetic</b>	<b>11*</b>	<b>1*</b>
	<b>Non-diabetic</b>	<b>0*</b>	<b>9*</b>
<b>3</b>	<b>Diabetic</b>	<b>10</b>	<b>0</b>
	<b>Non-diabetic</b>	<b>2</b>	<b>12</b>

**\*Total # of data points is 12, 3 points were rejected as they resulted in outlying signals.**

# Biological noise affecting skin optical response

- 15 Insulin dependent diabetic patients,
- In-hospital stay for 3 days, two to three at a time
- Reference method, capillary blood glucose
- Known caloric intake
- Use medication as prescribed by their physicians
- Data of day one and two are used as a calibration set
- Data of day three as a prediction set
- Noise ceiling was estimated by using the calibration set to predict the third day data after randomizing the glucose values
- Calculated the  $R^2$  and determined the when  $R^2$  ranked higher than the  $R^2$  for fitting random numbers

# Biological Noise

Parameters	Years of diabetes duration	
	< 20	> 20
Number of volunteers	8	7
Mean age (years)	43.3 ± 13.8	55 ± 8.2
Duration of diabetes (years)	11.1 ± 4.2	24.3 ± 7.3
Body mass index	30.4 ± 7.3	28.5 ± 2.9
%HbA1c	7.2 ± 1.1	6.8 ± 0.9
Number of females	6	0
Number of males	2	7
Number (%) with R <sup>2</sup> ranking above noise ceiling	6 (75%)	2 (29%)
Number (%) with R <sup>2</sup> ranking below noise ceiling	2 (25%)	5 (71%)

# Observations

- Skin of diabetics differs from the skin of non-diabetics Human skin is affected with diabetes
- Diabetes affects optical/thermal properties of human skin
- It is possible to track glucose concentration changes for some patients, using thermo-optical response of human skin
- Duration of diabetes, and or gender affects thermo-optical response of human skin and the correlation between these properties and blood glucose levels

# Even if detection is achieved, there is a problem with error estimates

1. Calibration and prediction is patient-specific using multivariate analysis
2. Multivariate calculations result in SEP. standard error of prediction, over the whole glucose concentration range
3. In-vitro calculations using single variable gives a standard deviation at a given concentration.
4. Calculated SEP may present a problem at low hypoglycemic glucose concentrations


# Simulation of error estimates

## Assumptions:

1. Home glucose monitor data for a single patient run over a period of time will be used to calibrate NI measurements
2. NI results will be less precise and less accurate than in-vitro results
3. Simulated imprecision by adding a constant error to each data point and calculating the SEP for new fit to the in-vitro data
4. Simulated intercept bias and slope bias between simulated in vivo data and in vitro data

# Simulation Reference Data set

176 In-vitro data points provided by an insulin-dependent diabetic using his home-glucose meter





**Prediction data: Derived from the reference data set by including imprecision, slope bias and intercept bias**

# Imprecision 1

A 10 mg/dL imprecision led to SEP = 10.7 mg/dL



A 20 mg/dL imprecision led to SEP = 21.4 mg/dL



# Imprecision 2

A 30 mg/dL imprecision led to SEP = 32.1 mg/dL  
A 40 mg/dL imprecision led to SEP = 42.8 mg/dL

Data points in erroneous zones on the Clarke Error Grid will lead to erroneous intervention and endanger patient's life





# Imprecision 3

A 60 mg/dL imprecision led to SEP = 64.2 mg/dL

A 80 mg/dL imprecision led to SEP = 69.5.8 mg/dL

More data points in erroneous zones on the Clarke Error Grid will lead to erroneous intervention and seriously endanger patient's life

Approaches the case of a random distribution




# Example data

- Arnold; Transmission through the tongue , 5 patients spot test, SEP > 54 mg/dL
- Heise, reflectance of oral mucosa, OGTT, SEP = 54 mg/dL
- Samann et al, 10 patients, leave-one-out cross validation
  - Short term SEP 18.5 mg/dL - 54 mg/dL
  - Long term experiment 55.8 to 6 108 mg/dl, one patient 646.2 mg/dL
- Malin et al, selected population, 25 mg/dL
- For a review of latest performance: Khalil, Diabetes Technology and Therapeutics 5; 660-697 (2004)

# Fitting to a Random Distribution

SEP of a random distribution is 80.8 mg/dl

Present NI methods are not equivalent to Random Distribution but still are far away from being quantitative



# What do we need

- 1. Improve sensitivity of the measurements**
  - better selection of glucose-related signal
- 2. Improve specificity**
  - Body interface issues
  - Body/skin physiology issues
  - Calibration issue (sub-population calibration)
  - Decrease number of variables
- 3. Compartmentalization:**
  - Define and target small sample of tissue where glucose distribution can be homogeneous
- 4. Error estimate**
  - Must be narrowed, even tighter than the in-vitro case, if multivariate analysis is used